Deniz Koçak Göl

Deniz Koçak Göl

Auto-generated profile, based on publicly available information

Deniz Koçak Göl

Erciyes University Faculty of Medicine, Department of Pediatrics Hematology and Oncology, Kayseri, Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Trends in Pediatrics
Verified
Journal Article
Open access
PDF file
ŞAŞefika Akyol
Şefika Akyol
TGTuran Güzel
Turan Güzel
AÖAlper Özcan
Alper Özcan
SKSerap Karaman
Serap Karaman
MOMehmet Fatih ORHAN
Mehmet Fatih ORHAN
EÜEkrem Ünal
Ekrem Ünal
Objective: B-cell Non-Hodgkin Lymphoma (B-NHL) is an aggressive malignancy in children requiring prompt multidisciplinary management. This retrospective cohort study aims to evaluate the clinical characteristics, treatment outcomes, and impact of rituximab (RTX) in pediatric B-NHL patients. Methods: We retrospectively analyzed 62 pediatric B-NHL patients treated at tertiary centers. Patient demographics, clinical presentation, histopathological subtypes, disease stage, treatment regimens, and survival outcomes were assessed. Event-free survival (EFS) and overall survival (OS) rates were analyzed based on lactate dehydrogenase (LDH) levels and RTX administration. Results: The mean age at diagnosis was 8.73±4.3 years, with a male predominance (79%). The most common histological subtype was Burkitt lymphoma (BL) (53.2%), followed by diffuse large B-cell lymphoma (DLBCL) (33.8%). Advanced-stage disease (III-IV) was observed in 74.1% of cases. RTX was administered in 72.5% of patients, with a mean of 5.1±2.7 doses. Febrile neutropenia (FEN) was noted in 74.1%, with intensive care unit (ICU) admission required for seven patients. Mortality was observed in 12 (19.3%) patients, including all patients with primary immunodeficiency (PID). The 5-year EFS for the entire cohort was 67.2%, and OS was 81.3%. Patients with LDH 400 U/L (EFS: 49.6%, OS: 70.7%; p=0.004 and p=0.015, respectively). In RTX-treated patients without PID, EFS was 76.5% versus 73.2% in those without RTX, but the difference was not statistically significant (p=0.53). Conclusions: Although not statistically significant, EFS was found to be higher in the RTX-treated group, suggesting that adding RTX to standard chemotherapy regimens may improve survival, particularly for high-risk patients, though its benefit in low-risk cases remains uncertain. Despite improved survival, patients with PID had poor outcomes, likely due to increased infections and disseminated disease. Risk-adapted, targeted treatment strategies are essential for optimizing outcomes in pediatric B-NHL. Further large-scale, randomized controlled trials are needed to confirm the efficacy of RTX in different risk groups and to optimize treatment regimens for pediatric B-NHL.

24 April 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
VGVeysel Gök
Veysel Gök
AOAlper Ozcan
Alper Ozcan
FMFatma Türkan Mutlu
Fatma Türkan Mutlu
EYEbru Yılmaz
Ebru Yılmaz
DGDeniz Kocak Göl
Deniz Kocak Göl
EUEkrem Unal
Ekrem Unal
Inherited platelet disorders (IPDs) are characterized by thrombocytopenia, platelet dysfunction, or both, leading to recurrent bleeding and diagnostic challenges. Advances in genetic testing have significantly improved early and accurate diagnoses. This study aimed to evaluate the clinical and genetic spectrum of IPDs, identify diagnostic challenges, and assess outcomes of therapeutic interventions. We conducted a retrospective cohort study of 50 IPD patients. We performed clinical evaluations, peripheral smear analyses, and genetic testing to identify causative variants. Correlation between platelet counts, bleeding severity, and the effectiveness of treatments, such as hematopoietic stem cell transplantation and thrombopoietin receptor agonists, was analyzed. A total of 54.5% of cases showed autosomal dominant inheritance. Diagnostic delays were common, with many patients initially misdiagnosed as having immune thrombocytopenic purpura (ITP). There was a moderate, negative, statistically significant correlation between platelet counts and bleeding severity. Peripheral smear findings, such as stomatocytosis and macrothrombocytopenia, provided critical diagnostic clues. We identified novel mutations in GP1BA, ITGB3, NBEAL2, WAS, and MPL genes, which expanded our understanding of IPDs. Different treatment modalities were used. Hematopoietic stem cell transplantation was performed in severe systemic cases, such as Wiskott–Aldrich syndrome. Sitosterolemia was treated with ezetimibe. Thrombopoietin receptor agonists reduced bleeding in some patients. Integrating genetic, clinical, and laboratory findings is essential in providing accurate diagnoses and management of IPDs. Early genetic diagnosis and personalized therapeutic strategies improve outcomes. Future research should focus on functional studies of novel mutations and refining treatment protocols to enhance care for this complex population.

26 December 2022 in Journal of Translational and Practical Medicine
Verified
Journal Article
Open access
PDF file
ŞAŞefika Akyol
Şefika Akyol
DGDeniz Koçak Göl
Deniz Koçak Göl
EYEbru Yilmaz
Ebru Yilmaz
KKKaraman Karaman
Karaman Karaman
AÖAlper Özcan
Alper Özcan
EÜEkrem Ünal
Ekrem Ünal
Aim: Hemophilias are inherited bleeding disorders, in which the patients generally present with clinical complaints of hemarthrosis. Intracranial hemorrhage (ICH) is one of the severe bleeding types with the highest mortality and morbidity throughout childhood, as well as in patients with a diagnosis of hemophilia. Herein, a single-center experience of intracranial hemorrhage in children with hemophilia is presented. Materials and Methods: The files and hospital records of the patients with the diagnosis of hemophilia who were followed up by the Pediatric Hematology and Oncology Department of Erciyes University between the years 1993-2022 were evaluated retrospectively. Results: A total of 81 patients with hemophilia were evaluated. Among them, 9 patients developed ICH. All patients had severe diseases. The mean age of incidence ICH was 2,6 months (4 days- 8,7 months). All the ICH episodes were observed within the first year of life. Four patients were diagnosed with the ICH episode initially. None of the patients had primary prophylaxis. The majority of them were admitted with neurological signs and symptoms. There was no ICH-related mortality in our study and all of the patients are being followed up in our department. Conclusion: Intracranial hemorrhage remains important in patients with congenital bleeding disorders, especially in hemophilia; with difficulties in diagnosis, management, and treatment.

27 May 2025
Verified
Book Chapter
Closed access
DGDeniz Koçak Göl
Deniz Koçak Göl
EÜEkrem Ünal
Ekrem Ünal

27 May 2025
Verified
Book Chapter
Closed access
MYMehmet Yay
Mehmet Yay
DGDeniz Koçak Göl
Deniz Koçak Göl
EÜEkrem Ünal
Ekrem Ünal

23 March 2025 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
PDF file
ŞAŞefika Akyol
Şefika Akyol
DGDeniz Koçak Göl
Deniz Koçak Göl
AÖAlper Özcan
Alper Özcan
VGVeysel Gök
Veysel Gök
BDBaver Demir
Baver Demir
MKMusa Karakükçü
Musa Karakükçü
Aims: Infantile hemangioma (IH) is the most common benign vascular tumor in childhood. Diagnosis, treatment decisionmaking, and monitoring of the treatment are challenging. This study aims to investigate the utilization of platelet (PLT) indices as a marker in the follow-up of IH treatment. Methods: The patients who were admitted and followed up in the outpatient clinic of Erciyes University Department of Pediatric Hematology and Oncology were enrolled in the study. The demographical data, treatment results, and PLT indices of the patients at certain time points were analyzed retrospectively. PLT, mean platelet volume (MPV), and platelet distribution width (PDW) were measured at various time points: upon admission, after the first and second months of treatment, at treatment completion, and during rebound episodes in affected patients. Results: A general decrease in PLT, PDW, and MPV values was noted when comparing admission levels to the first month of treatment. The mean PLT count was 452.680/mm3 at admission, it decreased to 405.900/mm3 at the 1st month, 376.600/mm3 at the 2nd month and 359.900/mm3 at the end of treatment (p: 0,002). Besides MPV was evaluated, it was observed that while the mean was 10.43 fl at the time of admission, it decreased to 9.51 fl in the following months and the decline was statistically significant with a p value of 0,031. Lastly, regarding the mean PDW values, a decline was detected once again from 11.34 % to 10.2 % between the admission time and termination of the treatment with a statistically significant p value of